CliffBio
small molecule

ISOVUE-200

IOPAMIDOL

Loss of exclusivityOctober 2028FDA regulatory exclusivity expiry
CompanyBRACCO DIAGNOSTICS INC

Drug detail

Brand nameISOVUE-200
Active ingredientIOPAMIDOL
Strength41%
Dosage formINJECTABLE
RouteINJECTION
ModalitySmall molecule
FDA approvalJuly 1987
Marketing statusRX

Regulatory exclusivity

CodeExpires
I-975October 2028

More from BRACCO DIAGNOSTICS INC

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the FDA regulatory exclusivity expiry; estimates are projections, not legal advice.

ISOVUE-200 patent cliff — loss of exclusivity October 2028 | CliffBio